Skip to main navigation Skip to search Skip to main content

[11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT2A receptors: A PET study in healthy human subjects

  • Columbia University
  • GlaxoSmithKline

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

The dopamine D1 receptor antagonist radioligand [ 11C]NNC 112 has previously been reported to have 100-fold selectivity for the D1 receptor compared with the serotonin 5-HT2A receptor. In this study, we tested the selectivity by scanning seven healthy human research volunteers with [11C]NNC 112 before and after 2 mg of the antipsychotic drug risperidone, a dose that putatively blocks all 5-HT 2A receptors with negligible effect on D1 receptors. We found that specific binding in cortical regions was reduced by 20% to 30%, whereas the striatum showed no change. Based on the known relative densities of these receptors in humans, our results suggest 5- to 10-fold selectivity of [11C]NNC 112 for D1 versus 5-HT2A as opposed to 100-fold selectivity. These results suggest caution in interpreting data from studies using this tracer to measure cortical D1 receptors as well as the need for more selective radioligands to assess cortical D1 receptors.

Original languageEnglish
Pages (from-to)1733-1741
Number of pages9
JournalJournal of Cerebral Blood Flow and Metabolism
Volume27
Issue number10
DOIs
StatePublished - Oct 2007

Keywords

  • [C]NNC 112
  • Dopamine D receptors
  • PET
  • Risperidone
  • Selectivity
  • Serotonin 5-HT receptors

Fingerprint

Dive into the research topics of '[11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT2A receptors: A PET study in healthy human subjects'. Together they form a unique fingerprint.

Cite this